Clinical trials: System; Sclerosis
Amyotrophic Lateral Sclerosis
Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS
The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as compared to placebo, assessed by the 18-month…
- Trial name
- MITOTARGET (NCT00868166)
- Testing
- Olesoxime, Riluzole
- Where
- 15 sites in Belgium, France and 3 more
- Volunteers
- 512 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.
GSK2018682 is a potent and selective agonist for the sphingosine-1- phosphate receptor subtype 1 (S1P1) with the potential to be an effective treatment for multiple sclerosis (MS).
- Trial name
- P1A114919 (NCT01466322)
- Testing
- GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Raynaud's Disease
Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's Phenomenon
The purpose of this clinical study is to determine the response to two different dosage strengths of a topical nitroglycerin gel in patients with Raynaud's Phenomenon.
- Trial name
- NCT00480753
- Testing
- Nitroglycerin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MediQuest Therapeutics
Multiple Sclerosis, Relapsing-Remitting
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
This was a retrospective non-interventional study (NIS) of adult (≥18 years) multiple sclerosis (MS) patients on ofatumumab therapy in the United Kingdom (UK) using secondary data.
- Trial name
- NCT06897657
- Where
- United States
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
ALS (Amyotrophic Lateral Sclerosis)
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT07100119
- Testing
- LY4256984
- Where
- 12 sites in Belgium, Canada and 3 more
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis
A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in ALS Patients
This is a prospective study in a cohort of about 45 patients with ALS participating in the Neurosense PrimeC drug study (NCT05357950).
- Trial name
- NCT05407428
- Testing
- NeuraLight software-based platform
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- NeuraLight
Multiple Sclerosis, Urinary Bladder Diseases
Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns
This study will assess the impact of a systematic bladder health screening and disease education regimen as well as the implementation of a referral process on the quality of life of multiple sclerosis patients with bladder…
- Trial name
- NCT01930799
- Testing
- Systematic Screening and Education Regimen
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Allergan
Metachromatic Leukodystrophy
Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)
A subject was treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) product manufactured using the CliniMACS (Miltenyi Biotec) device, rather than the Max Sep (Baxter) device.
- Trial name
- NCT02084121
- Testing
- Enriched Hematopoetic Stem Cell Infusion
- Where
- United States
- Sponsor
- Talaris Therapeutics Inc.
Multiple Sclerosis
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.
This study is designed to compare injection skin (injection site) reactions when an antihistamine (Zyrtec®) or placebo is taken prior to performing daily Copaxone® injections.
- Trial name
- NCT00240032
- Testing
- glatiramer acetate injection with oral cetirizine hydrochloride
- Volunteers
- 80 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Interstitial Lung Disease, Scleroderma
Open-label Study With Bosentan in Interstitial Lung Disease
This study will asses the long term safety and efficacy of oral bosentan to patients suffering from Interstitial Lung Disease.
- Trial name
- BUILD 2 OL (NCT00319033)
- Testing
- bosentan
- Volunteers
- 132 people
- Sponsor
- Actelion
Moderate to Severe Systemic Sclerosis
A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis
To evaluate the efficacy and safety of KHK4827 in patients with systemic sclerosis who have moderate to severe skin thickening
- Trial name
- NCT03957681
- Testing
- KHK4827
- Where
- 6 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Alzheimer Disease, Mild Cognitive Impairment
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular
- Trial name
- RHAPSODY (NCT04939818)
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Amyotrophic Lateral Sclerosis
ALS Phase II Study of NX210c
This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- SEALS (NCT06365216)
- Testing
- NX210c
- Where
- 16 sites in France
- Volunteers
- 80 people
- Sponsor
- Axoltis Pharma
Relapsing Remitting Multiple Sclerosis
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT04711148
- Testing
- orelabrutinib
- Where
- 42 sites in United States, China and 2 more
- Volunteers
- 160 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Multiple Sclerosis
Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.
- Trial name
- NCT03209479
- Testing
- Glatiramer acetate
- Where
- Japan
- Volunteers
- 1,332 people
- Sponsor
- Teva Takeda Pharma Ltd.
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to investigate the safety and tolerability of intrathecal riluzole in adults with amyotrophic lateral sclerosis.
- Trial name
- NCT07093268
- Testing
- Intrathecal Riluzole
- Where
- 2 sites in Australia
- Volunteers
- 10 people
- Sponsor
- Brain Trust Bio
Multiple Sclerosis
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration…
- Trial name
- FREVIVA (NCT06141486)
- Testing
- Frexalimab, MRI contrast-enhancing agents
- Where
- 311 sites in United States, Argentina and 25 more
- Volunteers
- 943 people
- Sponsor
- Sanofi
Multiple Sclerosis
Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)
The trial aims to evaluate the effectiveness of a novel digital health application (levidex), which was designed to increase quality of life in persons with multiple sclerosis (MS).
- Trial name
- LAMONT (NCT06090305)
- Testing
- levidex, Control, treatment as usual (TAU)
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Gaia AG